Evaluation of one‐stage and chromogenic assays for the laboratory measurement of factor VIII activity following valoctocogene roxaparvovec infusion
- 6 June 2024
- journal article
- letter
- Published by Wiley in Haemophilia
- Vol. 30 (5) , 1221-1224
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- A global comparative field study to evaluate the factor VIII activity of efanesoctocog alfa by one‐stage clotting and chromogenic substrate assays at clinical haemostasis laboratoriesHaemophilia, 2023
- Valoctocogene Roxaparvovec Gene Therapy for Hemophilia ANew England Journal of Medicine, 2022
- Gene-produced FVIII: measure for measureBlood, 2020
- Activity of transgene-produced B-domain–deleted factor VIII in human plasma following AAV5 gene therapyBlood, 2020
- Guidelines on the laboratory aspects of assays used in haemostasis and thrombosisBritish Journal of Haematology, 2020
- Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia ANew England Journal of Medicine, 2020
- Laboratory measurement of factor replacement therapies in the treatment of congenital haemophilia: A United Kingdom Haemophilia Centre Doctors’ Organisation guidelineHaemophilia, 2019
- AAV5–Factor VIII Gene Transfer in Severe Hemophilia ANew England Journal of Medicine, 2017
- The use of enhanced half‐life coagulation factor concentrates in routine clinical practice: guidance from UKHCDOHaemophilia, 2016